Ben Solari

@breadcrumbsre Acquire less cyclical businesses who are complimentary to your products in the value chain or reduce COGs in the downturn

In all seriousness , what the best capital allocation decision when you’re massively overearning at the top of the cycle? Special div? Hoarding cash?

@TTRAmyloid Agree

$crvs is an obvious acquisition target to me better than $tern. But 2-3b is way too cheap. Should be a 15b+ acquisition. $Kymr and $apge are trash me 9000s.

@LucasSacerdote_ And what’s the short case? 45% is super high.. do people think thi is a donut? I have been looking into solar last few weeks as an emergent theme into ‘27 so this is an interesting story but surprised by massive EV/Equity disparity (as mentioned above) and the super high % short

Yep, that accurate. Though it's important to notice that 3/5 of their debt is for non-recourse project financing with their developer arm, and the remaining 2/5ths are from CSI. Both of them had/have public events valuing their equity way higher. (CSI is validated every day in the public markets; Recurrent received $500M at a $2.5B equity valuation from Blackrock. Their third business, US manufacturing, has virtually zero debt so far. (they have leases...)

$CSIQ has become my largest position. I am calling this: "The Great Solar Reckoning" The way Canadian Solar has been mistreated by the capital markets has reached the irrational point. Which gives way for a once-in-a-lifetime opportunity in my opinion. $1 billion USD in market capitalization for: - One of the biggest producers of solar globally (and in the US). +25GWs of Solar capacity world wide, with +5GWs, ramping to +10GWs in the US. - One of the most dominant renewable project developers in the Western Hemisphere, with pipelines of +80GWh, investments from Blackrock at a $2.5B valuation and multi-billion, multi-currency debt facilities to expand their operations. - Leader in BESS. Having spent YEARS studying $EOSE, I can appreciate the sheer size and scale of $CSIQ operations in BESS. Multiple, multi-GWh orders. They already have a 2.5GWh order for DC, something neither $EOSE nor $FLNC has yet. So much more that I could go on and on... I would recommend reading the whole article if you are intrigued. More to come as well very soon. NFA. DYOR. All pushback is encouraged!

@endpointarena Hey Michael - fan of the endpoint arena concept but don’t you think “APPROVED” is the wrong terminology to use here?

APPROVED. First-ever Phase 3 data for an in vivo CRISPR therapy . $NTLA

@pnani456 @doepke_michel RVMD alleging patent infringment

@doepke_michel and why then pre announce it AM - shady

$ERAS sell off, data AH. Why not pre-market? The market is skeptical.

@PersimmonTI What’s your take on CMPX?

$XBI Another Manic Monday Morning: $NTLA — Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema — 8:00AM. $CMPX — Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Biliary Tract Cancer — 8:00AM. $ORKA — Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial — 8:00AM.

@JerseyWild_ Damn the Jeter autographics is 🔥

@CoachDPorter @CardsThings Let me know if you want the Gold to match!

Beautiful 👑 Felix mailday from @CardsThings

@seedy19tron Curious would LQDA interest you again once legal overhang removed?

Just some quick commentary $nktr offering closed and then you have a few more catalysts and the big one Q4 + litigation news. Ph3 cash concerns sorted pretty much. My EOY TP $160 $abvx there’s a very good chance maint hit, Crohn’s hit. Or shall I say non zero chance for both events to readout positive and stock could close at $275+ by YE. $cogt gist is real , only game in town $70 by YE $bcrx earnings based on script data should be good and a few other catalysts YE TP $21 $anl I shed half at ~$16, letting the rest run $nxtc sold all at $12 was a tiny position anyways

@andrewpannu @lefttailguy Interested in checking it out, congrats on the launch!

We're launching Sleuth today. The intelligence platform for biopharma's highest-stakes decisions, in use at top companies in the world. To celebrate, we broke down the Chinese landscape: 18K+ assets & a map of the strategic white space. RT + comment "Sleuth" for access.

@AB1001_disciple @taobanker No he’s trying to get them to split out the Clinics business with the medical device business so they can trade on appropriate comps which he thinks generates 5-7x re-rating of combined co’s - merging them together a year ago was a terrible idea

@blippd @taobanker Isnt the largest shareholder trying to get them to essentially liquidate the business lol

I used to own a bunch of $BWAY at $1 USD. I could be retarded but I'm pretty sure this is happening because of SAINT. Based on this new Joe Rogan Trump malarky talking about no new treatments for depression, its clear the ozempic moment hasn't happened yet. @taobanker

@CapstackCapital @AtlasShrug1 Interesting! I think it’s an intriguing set up both fundamentally and thematically but also has massive short interest that could serve (or is currently serving) as a powder keg to turnaround story

Oh boy. My firm, well actually a good friend of mine and colleague actually valued the debt on it pre-BK and during BK for a large asset manager. Tbh, idk. I’d have to dig in more, and I do love a post-Rx name. They always felt too early to the game, and maybe now they shine. It’s been a long time since I looked at them, so I’ll have to check up and get back to you on it.

Finally someone is talking about the move to 800V DC. Everyone on FinTwit is out trying to find the next bottleneck in AI chip production or what have you. Like “ok, cool. You found a company that manufactures machines for xyz process in the semiconductor chain. Essentially a one-time purchase with little-to-no recurring / re-occurring revenue.” Meanwhile, there is a shift to 800V DC architecture that is going to actually happen with the $NVDA Kyber rollout that fundamentally changes the power delivery architecture for data centers. The shift changes the equation. Yet virtually no one wants to talk about it even though it’s staring you right in the face and with plenty of opportunities, like $AOSL, $MPWR $NVTS, $POWI etc., just on the semiconductor side alone. Other plays include $VRT $ETN $APH $TEL etc. The reliance of power ICs grows significantly. I really like $AOSL, which I believe is set to experience outsized growth, that the market is not appreciating, driven by a shift from training to inference which more CPU-heavy. Could $INTC be back??? Possibly. Panther Lake babayyyy. And with its recent news to take full control over its Ireland fab via repaying $14.9bn to the $APO JV, it seems like there’s gears turning under the hood of something larger occurring. It feels symbolic of a broader outlook improvement for INTC.

@CapstackCapital @AtlasShrug1 Thoughts on WOLF post restructuring?

@AtlasShrug1 Other Power Semis / plays I forgot to include: $VICR 2308.TW $TXN $ADI $POWI $6723.T $STM $ON

@a_a_free Really solid list.

Due to last run-up in some stocks like $RVMD, $APGE, $SYRE and $ORKA, I have reduced a lot in many core positions and closed some. My top 1-6 (60%) are : $COGT, $PRAX, $abvx, $IONS, $STOK, $TARS. My top 6-12 (35%) are : $IMVT, $VOR, $ORKA, $APGE, $NKTR, $RLMD. I have small positions (15%) in : $ANL, $CGEM, $AVBP, $IMNM, $SNDX, $CRNX.

@blippd This is why

$LQDA shorts who still need to buy 10m+ shares at some point

@shkrelicat Looks like your short? Of all the names to short I’m curious why this one 🤔

@BDC_Analyst This thing is a coiled spring - so much $$ on sidelines not wanting to be blindsided by legal ruling that could come any day now, but once that’s removed the next few (1-4?) weeks.. look out

> be $LQDA CEO > say confident in achieving $1B sales come 2027 > say you'll completely replace the incumbent in PAH > say you'll completely replace Oral therapies > say your drug and MRK's drug are synergistic > call out Ralinepag's toxicity > call out lack of data for "mythical" SMI > tell investors that Yutrepia is scriptsmaxxing > elaborate > leave Absolute Chad.